ASK PHARM released its performance for the first three quarters, with a net profit attributable to the parent company of 223 million yuan, a year-on-year increase of 75.81%

According to the Zhitong Finance APP, ASK PHARM released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 1.434 billion yuan, a year-on-year increase of 3.57%. The net profit attributable to shareholders of the listed company was 223 million yuan, a year-on-year increase of 75.81%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 186 million yuan, a year-on-year increase of 81.89%

Aosaikang Pharma Says ASKB589 Shows Positive Results in Clinical Trial

Aosaikang Pharma Says ASKB589 Shows Positive Results in Clinical Trial

Aosaikang: Innovative drug ASKB589 will announce clinical research data at the 2025 ESMO Annual Meeting

ASK PHARM announced that its subsidiary ASKGENE LIMITED will present clinical research data for the biopharmaceutical ASKB589 at the 2025 ESMO Annual Meeting. The drug, in combination with CAPOX and PD-1 inhibitors, has shown deep and lasting tumor remission and disease control in first-line treatment of advanced gastric cancer, with clear survival benefits. These positive clinical data will enhance the market competitiveness of the company's products

Aosaikang's subsidiary signs ASKG712 project licensing agreement

Aosaikang's holding subsidiary AskGene Pharma has signed a licensing agreement with Visara, allowing Visara to use the independently developed innovative drug ASKG712 in specific regions. This drug targets VEGF and ANG-2 and is currently undergoing Phase IIa clinical trials in China, showing good safety and efficacy. This collaboration will promote the research and commercialization of ASKG712, aligning with the company's strategic direction and is expected to have a positive impact on future performance

The innovative drug sector adjusted at the beginning of the trading session, with Aosaikang hitting the limit down, followed by declines in Cosunter, Jimin Health, Huili Pharmaceutical-W, Saili Medical, Rongchang Bio, Wanbangde, and others